Autonomix Medical, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, reporting financial results for the three and six months ended on that date.

Key Highlights

  • Net loss for six months: The company reported a net loss of $5,854 thousand for the six months ended September 30, 2026, compared to $10,788 thousand for the same period in 2025.
  • Quarterly net loss: Net loss for the three months ended September 30, 2026 was $3,126 thousand, versus $7,451 thousand for the same quarter in 2025.
  • Cash position: Cash and cash equivalents stood at $7,692 thousand as of September 30, 2026, up from $7,004 thousand at March 31, 2026.
  • Shares outstanding: Common shares issued and outstanding were 1,959,938 as of September 30, 2026, compared to 542,312 as of March 31, 2026, with 2,045,193 shares outstanding as of November 6, 2026.
  • Warrant exercise proceeds: Gross proceeds from the exercise of warrants were $7,503 thousand during the six months ended September 30, 2026.
  • Accumulated deficit: The accumulated deficit reached $72,948 thousand as of September 30, 2026, compared to $67,094 thousand at March 31, 2026.
  • Total stockholders' equity: Total stockholders' equity was $6,941 thousand as of September 30, 2026, up from $5,895 thousand at March 31, 2026.

Autonomix Medical Financial Results: September 30, 2026 Quarter and Half-Year

According to the filing, Autonomix Medical, Inc. (NASDAQ:AMIX) reported total operating expenses of $3,177 thousand for the three months ended September 30, 2026, consisting of $1,584 thousand in research and development costs and $1,593 thousand in general and administrative expenses. For the six-month period, total operating expenses were $5,947 thousand, with $3,098 thousand attributable to research and development and $2,849 thousand to general and administrative expenses. These figures compare to total operating expenses of $7,534 thousand and $10,955 thousand for the respective prior-year periods.

The company disclosed that interest income for the six months ended September 30, 2026 was $93 thousand, resulting in a loss before income taxes of $5,854 thousand for the half-year period. No income tax expense was recorded. The loss per share on a basic and diluted basis was $(2.51) for the three months and $(6.52) for the six months ended September 30, 2026, based on weighted average shares outstanding of 1,247,363 and 897,447, respectively. The filing notes that 2025 figures are "as revised."

The filing reported that net cash used in operating activities was $6,157 thousand for the six months ended September 30, 2026, compared to $6,421 thousand in the prior-year period. Cash flows from financing activities provided $6,852 thousand, driven primarily by gross proceeds of $7,503 thousand from warrant exercises, partially offset by direct transaction costs of $602 thousand and other items. The company also disclosed a fractional share buyback of $7 thousand in connection with a reverse stock split and settlement of restricted stock awards for statutory tax withholding of $17 thousand during the period.

What Was Disclosed

Autonomix Medical filed its quarterly report covering the period ended September 30, 2026, disclosing a net loss of $5,854 thousand for the half-year, cash of $7,692 thousand, and significantly increased share counts following warrant exercises, with total stockholders' equity of $6,941 thousand.